From TradingView · · 30s
Moderna's Genocidal Juggernaut
Moderna's cancer cure stock faces criticism as insider selling intensifies.
In brief
Moderna's cancer cure stock faces criticism as insider selling intensifies. Moderna's stock is criticized for being a 'genocidal juggernaut' with no cash flows despite high growth expectations. Originally reported by TradingView.
Moderna's Stock Status
Moderna's stock trades at 35x next year's sales but grows 15% annually.
Insider Selling Trend
Tens of millions in insider selling observed with no recent insider buys.
Cancer Cure Claims
Moderna claims to cure cancer but made money only during the global pandemic.
The short version
Moderna's stock is criticized for being a 'genocidal juggernaut' with no cash flows despite high growth expectations.
